Exosome Diagnostics Launches CLIA-Certified Laboratory in Cambridge, MA; Company Uses Exosome-Based Platform for Detection of Exosomal RNA and Cell-Free DNA; Cancer Liquid Biopsy Test to Launch Later in 2015

Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced, August 12, 2015, that it has opened a Clinical Laboratory Improvement Amendments (CLIA)-Certified laboratory in Cambridge, Massacusetts (near Boston). The state-of-the-art clinical services laboratory will manage analysis and reporting for several liquid biopsy tests that the company plans to launch this year for prostate, lung, and other solid tumor cancers. These novel diagnostics will help clinicians detect disease sooner and obtain access to real-time molecular insights that can help better inform treatment decisions for patients with cancer and other serious diseases. “Exosome Diagnostics is dedicated to effectively solving challenges in health care and overcoming barriers to disease detection, monitoring, and treatment,” said Thomas McLain, CEO of Exosome Diagnostics. “We are taking this important step to centralize our operations at our U.S. corporate headquarters in Cambridge, as we work to seamlessly launch new molecular diagnostics, while also accelerating the application of our technology platform to other important disease areas.” Exosome Diagnostics is currently developing a suite of innovative plasma- and urine-based liquid biopsies that analyze exosomal RNA (exoRNA) for biomarkers. The company’s technology platform is uniquely versatile, offering the additional capability to simultaneously isolate and analyze exoRNA and cell-free DNA (cfDNA) to enhance detection of rare mutations. Exosomes are messenger-containing or bearing vesicles released by all living cells into biofluids, such as plasma/serum, urine, cerebrospinal fluid, and saliva. Exosomes can, and often do, contain RNA, DNA and proteins from their cell of origin.
Login Or Register To Read Full Story